Compare SPXC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPXC | LCTX |
|---|---|---|
| Founded | 1912 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 255.4M |
| IPO Year | 1994 | 1996 |
| Metric | SPXC | LCTX |
|---|---|---|
| Price | $181.37 | $1.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $245.56 | $6.25 |
| AVG Volume (30 Days) | 353.4K | ★ 941.4K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.08 | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | ★ $2,265,100,000.00 | $14,556,000.00 |
| Revenue This Year | $16.07 | $109.40 |
| Revenue Next Year | $7.68 | N/A |
| P/E Ratio | $65.82 | ★ N/A |
| Revenue Growth | 14.17 | ★ 53.24 |
| 52 Week Low | $176.21 | $1.00 |
| 52 Week High | $251.08 | $2.09 |
| Indicator | SPXC | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 38.23 |
| Support Level | N/A | N/A |
| Resistance Level | $225.70 | $1.18 |
| Average True Range (ATR) | 5.52 | 0.05 |
| MACD | -1.12 | -0.00 |
| Stochastic Oscillator | 18.40 | 0.00 |
SPX Technologies Inc supplies engineered heating, ventilation, and air conditioning, or HVAC, products, as well as detection and measurement technologies and power equipment. The company operates through two reportable segments. The HVAC segment which generates the majority of the revenue for the company, designs, manufactures, installs, and services cooling products, as well as heating and ventilation products. The Detection and Measurement technologies segment designs, manufactures, and installs underground pipe and cable locators and inspection equipment, bus-fare collection systems, and others. Geographically, the company has its operations in the United States, Canada, China, the United Kingdom, and Others. It derives maximum revenue from United States.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.